Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Business acquisition

Revvity Acquires Human Cell Design

Analysis based on 6 articles · First reported Sep 09, 2026 · Last updated Sep 11, 2026

Sentiment
5
Attention
2
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The deal modestly strengthens Revvity's life sciences tools franchise in metabolic disease research, a growing area given demand for GLP-1-related discovery capabilities, but the undisclosed financial terms and small scale of the target limit near-term earnings impact. Market reaction was slightly negative, with RVTY shares reportedly down 2.3% since the announcement, reflecting limited immediate financial accretion and integration risk.

biotechnology life sciences tools pharmaceuticals

Revvity, Inc. (NYSE: RVTY) announced on September 9, 2026 that it has entered into a definitive agreement to acquire Human Cell Design (HCD), a France-based biotechnology company specializing in human cell models and preclinical research solutions for diabetes, obesity and other metabolic diseases. The acquisition is expected to add HCD's human pancreatic beta cell models, including its flagship EndoC-betaH5 model, to Revvity's Life Sciences portfolio, supporting drug discovery, screening and preclinical research, including applications in GLP-1 and other metabolic disease therapies. HCD also offers specialized media and reagents, preclinical research services and its proprietary NatLine cell-line development platform. The transaction is expected to close in Q4 2026 and is subject to customary closing conditions, including required regulatory approvals. Financial terms were not disclosed. Revvity CEO Prahlad Singh Patel said HCD brings differentiated human cell models that complement Revvity's broad portfolio of technologies supporting drug discovery and development. HCD founder and president Guillaume Costecalde said joining Revvity is expected to bring the company's human cell models and NatLine technology to a broader global customer base. Revvity reported 2025 revenue of $2.9 billion, employs approximately 11,000 people and is part of the S&P 500 index. Following the announcement, RVTY stock reportedly lost 2.3% since the announcement on Wednesday, while year to date the stock has gained 25%.

90 Revvity entered definitive agreement Human Cell Design
stock
Revvity is the acquirer, expanding its Life Sciences portfolio with HCD's human pancreatic beta cell models and preclinical research capabilities. The deal is expected to close in Q4 2026 subject to regulatory approvals, and its stock reportedly fell 2.3% since the announcement.
Importance 100.0 Sentiment 10.0
priv
Human Cell Design is the France-based acquisition target, bringing its EndoC-betaH5 cell models and NatLine platform to a broader global customer base under Revvity ownership.
Importance 90.0 Sentiment 40.0
per
Prahlad Singh Patel, president and CEO of Revvity, commented that HCD's differentiated human cell models complement Revvity's drug discovery technologies and enable more integrated customer solutions.
Importance 30.0 Sentiment 5.0
per
Guillaume Costecalde, founder and president of Human Cell Design, said joining Revvity is expected to bring the company's human cell models and NatLine technology to a broader global customer base.
Importance 25.0 Sentiment 5.0
cnt
France is the home country of the acquisition target Human Cell Design, adding a cross-border element to the transaction.
Importance 10.0 Sentiment 0.0
index
The S&P 500 is referenced as the index that acquirer Revvity is part of, providing context for the stock's performance comparison.
Importance 5.0 Sentiment 0.0
France related ↔ S&P 500
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.